Before starting tirzepatide , our experienced medical team will carefully review your health history and discuss your goals to determine if this medication is the best option for you
In 1966, they reported that healthy individuals experienced an immediate rise in plasma insulin following an intravenous injection of glucagon
Executive Summary Written by Jonathan Wright, British Clinical Pharmacist Last reviewed: February 2026 Glucagon-like peptide-1 (GLP-1) receptor agonists including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have transformed the treatment of obesity and type 2 diabetes
It is expected to be commercially available by 2026 or 2027, after the FDA approves the medication.
Drst U., SGLT2-H
As these drugs become more prevalent, companies across sectors must anticipate and adapt to the evolving consumer preferences of this growing demographic of previously overweight and obese. By embracing this shift, businesses can survive and thrive in a landscape increasingly defined by health-conscious consumers
